Latest Fractyl Health News & Updates

See the latest news and media coverage for Fractyl Health. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Fractyl Health

Developer of metabolic therapies for obesity and type 2 diabetes

fractyl.com
Headquarters
Burlington, United States
Founded year
2010
Company type
Public company
Number of employees
100–200

Latest news about Fractyl Health

Company announcements

  • Fractyl Health

    Fractyl Health highlights REMAIN-1 trial results

    Results show reduced weight regain after GLP-1 discontinuation using Revita®. Dr. Sullivan presents six-month data at DDW2026 on May 4th.

  • Fractyl Health

    Fractyl Health reports Q4 and full year 2025 financial results

    Announces completed REMAIN-1 randomization, new post-hoc analyses showing dose-dependent effects, FDA feedback, and cash runway into early 2027.

  • Fractyl Health

    Fractyl Health completes randomization in REMAIN-1 Pivotal Cohort

    The double-blind, sham-controlled study evaluates Revita for weight maintenance after GLP-1 discontinuation. Topline 6-month data expected early Q4 2026.

  • Fractyl Health

    Fractyl Health announces positive 6-month REMAIN-1 data

    Revita shows sustained weight maintenance, improved cardiometabolic profile, and reduced cravings post-GLP-1 vs sham. FDA De Novo feedback expected Q2 2026.

Unlock all announcements with a

Media coverage

Unlock all articles with a

Never miss news about Fractyl Health

Track Fractyl Health and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.